Skyrizi Launch Skyrockets, Boosting AbbVie Hopes For Humira Successors
Executive Summary
AbbVie’s balancing act sees Skyrizi/Rinvoq launches and strong hematologic cancer strength offset the continued erosion of Humira sales outside the US. Rinvoq gets off to a quick start in its US launch.
You may also be interested in...
AbbVie Maintains Xeljanz Safety Concerns Don’t Spill Over To Rinvoq
Responding to Pfizer post-marketing data indicating risk for CV events or cancer in patients taking Xeljanz, AbbVie tells Q4 earnings call that a more selective JAK inhibitor like Rinvoq will offer better safety.
AbbVie Investors Look For Stabilizing Botox Revenues In Q3 Financials
Reporting its first full quarter of financials since merging with Allergan, AbbVie will be scrutinized for whether its optimistic talk of a quick Botox rebound actually happened.
AbbVie Says Botox Business Recovering But Allergan Drags Down Q2 Financials
AbbVie reported revenue growth during the second quarter, with products like Rinvoq and Skyrizi leading the charge. But Allergan, despite growth for Vraylar and Ubrelvy, pushed down overall performance.